Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP-cure-B proof-of-concept trial of selgantolimod and nucleos(t)ide analogue discontinuation in HBeAg-negative chronic hepatitis B
2020-004376-18Phase 2Active
- Sponsor
- ANRS
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selgantolimod, entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide in Chronic Hepatitis B (CHB) (3 arms), sponsored by ANRS. Primary endpoint: HBsAg decline response. Started Mar 2021; status: active.
02
Drugs
selgantolimodentecavirtenofovir disoproxil fumaratetenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2020-004376-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004376-18.